ReShape Lifesciences Inc

ReShape Lifesciences — EnteroMedics — IPO Roadshow (November 2010)

22 slides from ReShape Lifesciences's IPO roadshow presentation, Nov 23, 2010

  1. Slide 1: Management Presentation

    Management Presentation November 2010

  2. Slide 2: Free Writing Prospectus Disclosure

    Free Writing Prospectus Disclosure IssuerFreeWritingProspectus FiledPursuantto SECRule433 On November 10, 2010, the issuer, EnteroMedicsInc., filed a RegistrationStatementon FormS-1 (RegistrationNo. 333-170503) with the Securitiesand ExchangeCommission(the “SEC”)with respectto the offeringto whichth

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement Thispresentationcontainsforward-looking statementsaboutEnteroMedicsInc.Ouractualresultscoulddiffermateriallyfrom thosediscussed dueto knownandunknownrisks,uncertaintiesandother factorsincludingour limitedhistoryof operations; our lossessinceinceptionand for the foreseeablefutur

  4. Slide 4: Offering Summary

    Offering Summary Issuer: EnteroMedics Inc. Ticker / Exchange: ETRM / NASDAQ Offering Size: 12 million shares (100% primary) Warrant Coverage: 100% Coverage (25% premium to offer price) Over-Allotment: 15% (100% primary) Use of Proceeds: Continue work toward US regulatory approval International comme

  5. Slide 5: Background and Investment Highlights

    Background and Investment Highlights Founded in 2002 to create neuroblocking “pacemaker”for obesity (Maestro® System) that would: – Targetthe shortcomingsof existingtreatments by addressingthe unmet needsof 26 million eligible surgical candidates – Control the co-morbidities of diabetes and high blo

  6. Slide 6: The Obesity Epidemic

    The Obesity Epidemic 1/3 of US adults are obese (2/3 of Australian adults are overweight or obese) – More than 72 million people in the US (Body Mass Index “BMI” >30) – 1 in 8 deaths in the US are caused by an overweight/obesity related illness – CDC estimates an overall economic cost of obesity of

  7. Slide 7: Current Treatments

    Current Treatments Pharmaceuticals Bariatric Surgery Less Invasive More Invasive Serious safety concerns Bypass & sleeve surgery irreversible and risky Less effective for morbid obesity Adjustable gastric bands have long-term follow- – Limited weight loss up burdens (e.g. vomiting, quarterly adjustm

  8. Slide 8: Role of the Vagus Nerve

    Role of the Vagus Nerve Vagus nerve controls: – Sensation of hunger 20% of vagus – Expansion, fullness and emptying nerve fibers send of stomach instructions from the brain – Digestive enzyme secretion Severing the vagus nerve 80% of vagus (vagotomy) causes: nerve fibers send messages – Reduced appe

  9. Slide 9: VBLOC Therapy

    VBLOC Therapy Delivered via the Maestro System VBLOC Therapy – Intermittent neuroblockingtechnology – Pacemaker-like device (Maestro System) including leads laporoscopically implanted on the intra-abdominal vagal trunks – Vagusnerve controls hunger; VBLOC Therapy blocks vagusnerve signals, therefore

  10. Slide 10: Compelling Clinical Results

    Compelling Clinical Results Significant impact on hunger and fullness drives successful weight loss Earlier Fullness and Less Hunger Reduced Portion Size Reduced Calories 90% 2250 30% Earlier Protein Carbohydrates Fat % EWL from 25% fullness 2000 Implant 20% 60% 1750 20% 15% 10% 30% 1500 5% 0% 1250

  11. Slide 11: The Maestro System Clinical Experience

    The Maestro System Clinical Experience Safety Efficacy No deaths or therapy related SAEs; Low SAE rate Clinically significant weight-loss Positive safety profile Control of major co-morbidities Low 1-year surgical revision rate – Diabetes and hypertension Study Location # Patients Study Efficacy ~40

  12. Slide 12: Maestro System: Usage equals Results

    Maestro System Usage equals RESULTS EMPOWER Trial Outcome Mean Excess Weight Loss (EWL) by Hours of Use in Treatment Group 0 “Dose Effect”shows clear < 6hr correlation between -5 (n = 25) average EWL and the -10 number of hours of device 6 - 9hr (n = 61) use -15 – Demonstrates efficacy -20 9 - 12hr

  13. Slide 13: EMPOWER Trial Analysis

    EMPOWER Trial Analysis 294 patient US study using the first generation Maestro RF System An unanticipatedtherapeuticeffect wasdeliveredto the placeboarm – Received a low-charge from safety and system diagnostic checks – Post-study Rat Model demonstrated low charge effect Both groups experienced sign

  14. Slide 14: US RECHARGE Trial

    US RECHARGE Trial Pivotal Trial for US Approval Use next generation implantable device VBLOC-DM2 Enable Trial Excess Weight – More convenient Loss (EWL) % – Hours of use controlled by device Approximate Hours of Use = 14 Hours Placebo group will receive non-active 28 device (without leads to the vag

  15. Slide 15: Significant Promise in Treatment of Co-Morbidities

    Significant Promise in Treatment of Co-Morbidities Diabetes and Hypertension Clinically significant effect of VBLOC on two major co-morbidities – Diabetes – Cardiovascular / blood pressure Improvements were immediate and sustained – Diabetes: • HbA1c reduced to below 7.0% • Diabetes control level se

  16. Slide 16: Commercialization in Australia

    Commercialization in Australia Australia is expected to be the first market to commercially launch the Maestro System – Historical leadership with new obesity treatments – Extensive clinical experience with Maestro in the hands of experienced surgeons and bariatric follow up teams • In an Australian

  17. Slide 17: Upcoming Planned Catalysts

    Upcoming Planned Catalysts 2011 2012 Ongoing Clinical Data Q1 Begin ReCharge Enrollment Q1 Receive CE Mark for RC Device 2H TGA Approval in Australia (commence sales) Australian Revenue 2H Complete ReCharge Enrollment Release ReCharge Trial Data 2H Premarket Approval (PMA) Submission Q4 Explore Othe

  18. Slide 18: Experienced Board of Directors & Management Team

    Experienced Board of Directors & Management Team Highly experienced management team and Board of Directors Name Role at EnteroMedics Background Mark B. Knudson, PhD President and CEO and Chairman of the Board Faculty, University of Washington School of Medicine Founder and Director of multiple medic

  19. Slide 19: Financial Summary

    Financial Summary Balance Sheet Data Diluted Shares Outstanding As of September 30, 2010 As converted, as of October 31, 2010 Cash and cash equivalents $13.3 million* Common Shares 10.9 million Warrants 4.9 million Options 0.8 million Diluted Shares Outstanding 16.6 million *Includes $781K of Series

  20. Slide 20: Value Creation Opportunity

    Value Creation Opportunity Significant revenue opportunity in the US Upside – Maestro System can attract a larger percentage of the obesity market – A metabolic solution with impact beyond obesity • Diabetes, hypertension and other GI maladies Obesity treatment is a major category for large pharmace

  21. Slide 21: Investment Highlights

    Investment Highlights Next generation device to treat obesity Effectiveness and safety supported by multiple trials and 400+ implants Clear and significant advantages over current obesity treatments Controls the co-morbidities of diabetes and high blood pressure IDE approved for second US pivotal tr

  22. Slide 22: EnteroMedics

    s geen eee =~ ~ ORCHESTRATING OBESITY SOLUT

EnteroMedics — IPO Roadshow (November 2010) on 6ix